-
Mashup Score: 0Litfulo Approved for Severe Alopecia Areata in Adults, Adolescents - 11 month(s) ago
Litfulo is supplied as a 50mg capsule and is expected to be available in the coming weeks.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
CAL02 is a first-in-class non-biological, broad-spectrum, bacterial virulence neutralizer.
Source: MPRCategories: Infectious Disease, Latest HeadlinesTweet-
“CAL02 is a first-in-class non-biological, broad-spectrum, bacterial virulence neutralizer. The investigational treatment consists of proprietary, engineered liposomes that capture and neutralize bacterial toxins” https://t.co/pAi3dzKkiC
-
-
Mashup Score: 0MPR Weekly Dose Podcast #163 - 11 month(s) ago
FDA revoke Emergency Use Authorization for COVID-19 vaccine; New approval for treatment of iron deficiency in patients with heart failure; Lumryz now available for excessive daytime sleepiness; Vowst approved for C. difficile infection; Prevymis approved for prophylaxis of CMV disease in adult kidney transplant recipients.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
🎧 Latest MPR Pod! 🔸 FDA revoke EUA for COVID-19 vax; ❤️ Approval for Tx of iron deficiency in patients with HF; 😴 Lumryz available for daytime sleepiness; 💊 Vowst approved for C. difficile infection; & 🔹 Prevymis prophylaxis for CMV disease. https://t.co/toAESnPlGN
-
-
Mashup Score: 0Injectafer Approved for Iron Deficiency in Adults With Heart Failure - 11 month(s) ago
The approval was based on data from the randomized, double-blind, placebo-controlled phase 4 CONFIRM-HF trial.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The approval was based on data from the Confirm-HF trial, which assessed Injectafer in adults with iron deficiency and chronic heart failure. https://t.co/2cJ33Hxm6G
-
-
Mashup Score: 0
Prevymis is a CMV DNA terminase complex inhibitor.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Phase 3 trial results showed the incidence of CMV syndrome, in adult kidney transplant recipients, was 8- and 11% in a letermovir and valganciclovir treated arm, respectively. https://t.co/umGylJ4YbL
-
-
Mashup Score: 0Janssen COVID-19 Vaccine No Longer Authorized for Emergency Use - 11 month(s) ago
The last lots of the vaccine purchased by the US government have expired.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
According to Janssen, the last lots of the vaccine purchased by the US government have expired. https://t.co/agvdBZZbGZ
-
-
Mashup Score: 0MPR Weekly Dose Podcast #162 - 11 month(s) ago
New vaccine to prevent lower respiratory tract disease; A new treatment for heart failure; Concerns over compounded semaglutide; New extended-release opioid use disorder treatment; Treatment for motion sickness shows promise.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
📢 New MPR podcast! 🔸 Vaccine to prevent RSV; 🔹 Treatments for heart failure, opioid use disorder; 🔸 Concerns over semaglutide compounding; and 🔹 motion sickness drug shows promise. https://t.co/7FXRSkHh71
-
-
Mashup Score: 0
The increasing number of indications for second-generation antiandrogens may result in a large group of men at risk for toxic effects.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The increasing number of indications for second-generation antiandrogens may result in a large group becoming at risk for toxic effects. https://t.co/DXP2uVRUyl
-
-
Mashup Score: 1Ayvakit Approved for Indolent Systemic Mastocytosis - 12 month(s) ago
The approval was based on data from the double-blind, placebo-controlled PIONEER trial.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
FDA gives nod to Ayvakit for indolent systemic mastocytosis. https://t.co/oRFfmg0GMr
-
-
Mashup Score: 0Oral Semaglutide Achieves Superior Weight Loss Compared With Placebo in Phase 3 Trial - 12 month(s) ago
A greater proportion of patients who received oral semaglutide achieved superior weight loss after 68 weeks compared with those who received placebo.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
“We are very pleased with the weight loss demonstrated by the once-daily oral formulation of semaglutide in obesity." https://t.co/vSqygRRFm6
-
Alopecia treatment given green like for those 12 years and older. #alopecia https://t.co/VFqKnlZuRi